
-
AbbVie NYSE:ABBV AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Location: 1 North Waukegan Road, North Chicago, IL, 60064-6400, United States | Website: https://www.abbvie.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
389.9B
Cash
5.176B
Avg Qtr Burn
N/A
Short % of Float
1.12%
Insider Ownership
0.10%
Institutional Own.
74.50%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RINVOQ (upadacitinib) Details Giant Cell Arteritis (GCA) | Approved Quarterly sales | |
EMRELIS™ (telisotuzumab vedotin-tllv) Details NSCLC With High c-Met Protein Overexpression | Approved Quarterly sales | |
TrenibotulinumtoxinE (TrenibotE) Details Moderate to Severe Glabellar Lines | BLA Acceptance for review | |
Tavapadon (adjunct with L-Dopa) Details Parkinson's disease, Brain disease | Phase 3 Update | |
Tavapadon Details Parkinson's disease, Brain disease | Phase 3 Update | |
Phase 2 Update | ||
Emraclidine (CVL-231) Details Brain disease, Schizophrenia | Phase 2 Update | |
Darigabat (CVL-865) Details Epilepsy | Phase 2 Update | |
NX-13 Details Ulcerative colitis | Phase 2 Update | |
Darigabat Details Social Anxiety Disorder, Panic Disorder | Phase 2 Update | |
CVL-354 Details Major depressive disorder | Phase 1 Update | |
Emraclidine (CVL-231) Details Brain disease, Neurodegenerative disease, Alzheimer's disease | Phase 1 Update |